PharmaCyte Biotech closes $7 million financing round
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025 9:15 AM EDTLAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company), today announced the closing of its previously announced $7 million financing.
As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Companys most recent 10K. With the addition of the $7 million in proceeds from this financing, the Companys balance sheet has been further strengthened, providing significant financial flexibility to support its ongoing business initiatives and strategic growth opportunities.
The successful completion of this financing is a welcome milestone as we... More
